{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:53:04Z","timestamp":1792803184391,"version":"4.5.0"},"reference-count":37,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI17C1807"],"award-info":[{"award-number":["HI17C1807"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["NRF-2021R1I1A2048905"],"award-info":[{"award-number":["NRF-2021R1I1A2048905"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["HI17C1807"],"award-info":[{"award-number":["HI17C1807"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1I1A2048905"],"award-info":[{"award-number":["NRF-2021R1I1A2048905"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Research Institute of Bioscience &amp; Biotechnology","award":["HI17C1807"],"award-info":[{"award-number":["HI17C1807"]}],"id":[{"id":"https:\/\/ror.org\/03ep23f07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Korea Research Institute of Bioscience &amp; Biotechnology","award":["NRF-2021R1I1A2048905"],"award-info":[{"award-number":["NRF-2021R1I1A2048905"]}],"id":[{"id":"https:\/\/ror.org\/03ep23f07","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Coralmycins, such as coralmycin A and DH-coralmycin A, have novel molecular skeletons and have been reported to exhibit potent antibacterial activity against standard Gram-positive bacterial strains. Here, the in vitro antibacterial activity against an extensive clinical isolate collection, time-kill kinetics, pharmacokinetics (PK), and in vivo efficacy of coralmycins were studied. Coralmycin A showed potent antibacterial activity with an MIC90 of 1 mg\/L against 73 clinical methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci isolates, which was 2\u20138 times higher than the corresponding activities of DH-coralmycin A, vancomycin, daptomycin, and linezolid, and against 73 vancomycin-resistant Enterococcus and Streptococcus pneumoniae isolates, which was 4\u201316 times higher than the corresponding activities of DH-coralmycin A, daptomycin, and linezolid. Pharmacokinetic analysis after i.v. injection showed that coralmycins have a moderate volume of distribution and moderate-to-high clearance in mice. The coralmycin A and DH-coralmycin A bioavailability values were 61.3% and 11.7%, respectively, after s.c. administration. In a mouse respiratory tract infection model, coralmycin A showed bacteriostatic and bactericidal in vivo efficacies at an s.c. administration of 4 and 100 mg\/kg bid, respectively; these efficacies were similar to those of vancomycin at 4 and 20 mg\/kg bid, respectively. The present findings indicate that coralmycin A has great potential as a new class of antibiotic for treating infections caused by multidrug-resistant Gram-positive bacteria.<\/jats:p>","DOI":"10.3390\/antibiotics11070902","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T09:41:10Z","timestamp":1657100470000},"page":"902","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antibacterial Activity against Clinical Isolates and In Vivo Efficacy of Coralmycins"],"prefix":"10.3390","volume":"11","author":[{"given":"Ha-Young","family":"Choi","sequence":"first","affiliation":[{"name":"Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Yusong, Daejeon 34141, Korea"},{"name":"Department of Bio-Molecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (UST), Yusong, Daejeon 34141, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Yusong, Daejeon 34141, Korea"},{"name":"Department of Bio-Molecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (UST), Yusong, Daejeon 34141, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Rok","family":"Kim","sequence":"additional","affiliation":[{"name":"School of Life Science, Handong Global University, Pohang 37554, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-3281","authenticated-orcid":false,"given":"Taehui","family":"Yang","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Yusong, Daejeon 34141, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjoo","family":"Ahn","sequence":"additional","affiliation":[{"name":"Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yusong, Daejeon 34114, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-8477","authenticated-orcid":false,"given":"Dongeun","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3613-5380","authenticated-orcid":false,"given":"Jin-Hwan","family":"Kwak","sequence":"additional","affiliation":[{"name":"School of Life Science, Handong Global University, Pohang 37554, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Gon","family":"Kim","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Yusong, Daejeon 34141, Korea"},{"name":"Department of Bio-Molecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (UST), Yusong, Daejeon 34141, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nature.2017.21550","article-title":"The drug-resistant bacteria that pose the greatest health threats","volume":"543","author":"Willyard","year":"2017","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkg104","article-title":"Linezolid resistance in clinical isolates of Staphylococcus aureus","volume":"51","author":"Wilson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1099\/jmm.0.000566","article-title":"Detection of high levels of resistance to linezolid and vancomycin in Staphylococcus aureus","volume":"66","author":"Azhar","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mittal, G., Bhandari, V., Gaind, R., Rani, V., Chopra, S., Dawar, R., Sardana, R., and Verma, P.K. (2019). Linezolid resistant coagulase negative staphylococci (LRCoNS) with novel mutations causing blood stream infections (BSI) in India. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4368-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2174\/1871526519666190807152850","article-title":"Linezolid Resistance in Staphylococcus haemolyticus\u2014Case Series and Review of Literature","volume":"20","author":"Gupta","year":"2020","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1128\/AAC.00533-10","article-title":"Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment","volume":"54","author":"Lee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1021\/acs.jnatprod.6b00294","article-title":"Isolation of Coralmycins A and B, Potent Anti-Gram Negative Compounds from the Myxobacteria Corallococcus coralloides M23","volume":"79","author":"Kim","year":"2016","journal-title":"J. Nat. Prod."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14605","DOI":"10.1002\/anie.201409964","article-title":"Cystobactamids: Myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity","volume":"53","author":"Baumann","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kim, B.M., Minh, N.V., Choi, H.Y., and Kim, W.G. (2019). Coralmycin Derivatives with Potent Anti-Gram Negative Activity Produced by the Myxobacteria Corallococcus coralloides M23. Molecules, 24.","DOI":"10.3390\/molecules24071390"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12760","DOI":"10.1002\/anie.201705913","article-title":"Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens","volume":"56","author":"Huttel","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12755","DOI":"10.1002\/anie.201705387","article-title":"Total Syntheses of Cystobactamids and Structural Confirmation of Cystobactamid 919-2","volume":"56","author":"Cheng","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1039\/C9SC04769G","article-title":"Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy","volume":"11","author":"Testolin","year":"2020","journal-title":"Chem. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nchembio.1734","article-title":"The gyrase inhibitor albicidin consists of p-aminobenzoic acids and cyanoalanine","volume":"11","author":"Cociancich","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.40.3.799","article-title":"In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis","volume":"40","author":"Kaatz","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1002\/jps.21317","article-title":"Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding","volume":"97","author":"Waters","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3201\/eid0901.020172","article-title":"Dead bugs don\u2019t mutate: Susceptibility issues in the emergence of bacterial resistance","volume":"9","author":"Stratton","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ja.2011.5","article-title":"Bacteriostatic versus bactericidal activity of ciprofloxacin in Escherichia coli assessed by flow cytometry using a novel far-red dye","volume":"64","author":"Silva","year":"2011","journal-title":"J. Antibiot."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/39.suppl_2.23","article-title":"Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin\/tazobactam against six anaerobes","volume":"39","author":"Spangler","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4155\/fmc.10.224","article-title":"In vitro pharmacokinetic\/pharmacodynamic models in anti-infective drug development: Focus on TB","volume":"2","author":"Vaddady","year":"2010","journal-title":"Future Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1126\/science.7604262","article-title":"Common virulence factors for bacterial pathogenicity in plants and animals","volume":"268","author":"Rahme","year":"1995","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.coph.2008.06.010","article-title":"PK\/PD: New insights for antibacterial and antiviral applications","volume":"8","author":"Schmidt","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/civ498","article-title":"Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice","volume":"61","author":"Labreche","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2006.08.026","article-title":"Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management","volume":"377","author":"Dasgupta","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/j.1875-9114.1988.tb04058.x","article-title":"Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions","volume":"8","author":"LeBel","year":"1988","journal-title":"Pharmacotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00281-17","DOI":"10.1128\/AAC.00281-17","article-title":"Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","unstructured":"Clinical and Laboratory Standards Institute (2013). Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Third Informational Supplement M100-S23, CLSI."},{"key":"ref_37","unstructured":"National Committee for Clinical Laboratory Standards (1999). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A, NCCLS."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/7\/902\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:43:27Z","timestamp":1760139807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/7\/902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["antibiotics11070902"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11070902","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}